Leukocyte surface

The leukocyte surface refers to the plasma membrane of white blood cells, which serves as the primary interface for immune signaling and environmental interaction (Zola, 2006). It is populated by a vast array of proteins, including receptors, ion channels, and adhesion molecules, many of which are classified under the Cluster of Differentiation (CD) system (NIH, 2006). While the term 'leukocyte surface' is a cellular location rather than a single molecular target, it is the site of numerous high-value therapeutic targets such as CD20, CD47, and PD-1 (ChEMBL; Cancer.gov). Drugs targeting these surface molecules are used to treat a wide range of conditions, including hematologic malignancies, solid tumors, and chronic inflammatory diseases (Frontiers in Immunology, 2022). For instance, monoclonal antibodies like rituximab target CD20 to treat B-cell lymphomas, while checkpoint inhibitors target PD-1 to restore anti-tumor immunity (PubMed). The surface also facilitates critical processes such as leukocyte rolling, adhesion, and transendothelial migration through molecules like integrins and selectins (Physiology.org). Because the term encompasses thousands of distinct proteins with diverse biological roles, it is considered too broad for specific therapeutic characterization and usually requires the identification of a specific surface antigen to be a valid drug target (GlobalData).

Other names

White blood cell surfaceLeukocyte membraneLeukocyte surface antigenCD antigensLeukocyte common antigenLeukocyte surface antigen CD47

Drugs targeting the leukocyte surface typically bind to specific membrane-bound proteins (antigens or receptors) to modulate immune cell function, induce targeted cell lysis (e.g., ADCC, CDC), or inhibit pathological cell-cell interactions (Zola, 2006; NCI Drug Dictionary).